FDA D.I.S.C.O. Burst Edition: FDA Approvals of Xalkori for patients 1-21 years with ALK-positive ALCL and Enhertu for adult patients with locally advanced or metastatic HER2-positive gastric or gastroesophageal adenocarcinoma

FDA D.I.S.C.O. Burst Edition: FDA Approvals of Xalkori for patients 1-21 years with ALK-positive ALCL and Enhertu for adult patients with locally advanced or metastatic HER2-positive gastric or gastroesophageal adenocarcinoma

Source: FDA Center for Drug Evaluation and Research - What's New - February 9, 2021 Category: Drugs & Pharmacology Authors: FDA Source Type: news